Document Detail


Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
MedLine Citation:
PMID:  16397017     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The presence of del(5q), either as the sole karyotypic abnormality or as part of a more complex karyotype, has distinct clinical implications for myelodysplastic syndromes (MDS) and acute myeloid leukemia. The 5q- syndrome, a subtype of low-risk MDS, is characterized by an isolated 5q deletion and <5% blasts in the bone marrow and can serve as a useful model for studying the role of 5q deletions in the pathogenesis and prognosis of myeloid malignancies. Recent clinical results with lenalidomide, an oral immunomodulatory drug, have shown durable erythroid responses, including transfusion independence and complete cytogenetic remissions in patients with del(5q) MDS with or without additional chromosomal abnormalities. These results indicate that lenalidomide can overcome the pathogenic effect of 5q deletion in MDS and restore bone marrow balance. The data provide important new insights into the pathobiology of 5q chromosomal deletions in myeloid malignancies.
Authors:
Aristoteles A N Giagounidis; Ulrich Germing; Carlo Aul
Related Documents :
16424877 - Population-based demographic study of karyotypes in 1709 patients with adult acute myel...
18726917 - Transient myelodysplastic syndrome in x-linked agammaglobulinemia with a novel btk muta...
1061637 - Chromosomes and causation of human cancer and leukemia. xi. correlation of karyotypes w...
3422167 - Prognostic significance of chromosome analysis in de novo acute myeloid leukemia (aml).
9283597 - Comparative genomic hybridization analysis of human neuroblastomas: detection of distal...
3043997 - Risk factors and genetic background for alzheimer's disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  12     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-06     Completed Date:  2006-02-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5-10     Citation Subset:  IM    
Affiliation:
St. Johannes Hospital, Medizinische Klinik II, Duisburg, Germany. gia@krebs-duisburg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chromosome Deletion*
Chromosomes, Human, Pair 5 / genetics*
Clinical Trials as Topic
Female
Hematopoiesis / drug effects,  genetics
Humans
Male
Myeloproliferative Disorders / genetics*,  therapy
Prognosis
Thalidomide / analogs & derivatives,  therapeutic use
Chemical
Reg. No./Substance:
191732-72-6/lenalidomide; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coelution of other proteins with albumin during size-exclusion HPLC: Implications for analysis of ur...
Next Document:  Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to ...